Janssen has added the first two first data centers to a Europe-wide program to gain better real-world evidence (RWE) on blood cancers.
The Hematology Outcomes Network in Europe (HONEUR) scheme is aimed at improving treatment for patients with blood cancer by using real-world data through a secure, collaborative platform. It was created to help overcome the challenges of Europe’s scattered data collection.
The UK’s Leicester Royal Infirmary and The Registry of Monoclonal Gammopathies (RMG) in the Czech Republic are the first sites to join the scheme.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze